Pfizer leads across stewardship metrics and is ranked among top two large R&D pharmaceutical companies in the fight against antimicrobial resistance (AMR)*1
The 2020 AMR Benchmark highlighted key areas of our leadership, including:
|Pfizer is ranked first across stewardship metrics. Through a pilot established in 2019, Pfizer fully decoupled sales bonuses from volumes for antibacterial and antifungal medicines in the UK and partially decoupled bonuses from sales volumes in other countires. Pfizer was also recognised as the first company to share raw data on resistance collected via our open-access ATLAS surveillance program.1|
|Pfizer is a leading company when it comes to filing relevant on-patented products for registration in low- and middle-income countires and taking steps to ensure continuous supply.1|
|Pfizer is one of the few large research-based pharmaceutical companies still active in R&D for antibacterial medicines and vaccines.1|
|Pfizer has a comprehensive environmental risk-mangement strategy for our manufacturing sites, and those of our suppliers, to limit AMR.1|
*The Access to Medicine Foundation AMR Benchmark Report
The Access to Medicine Foundation published its 2020 Antimicrobial Resistance Benchmark on February 2020. The bi-yearly report evaluates our industry’s progress in the fight against antimicrobial resistance (AMR). The Foundation's Benchmark provides an independent comparison of 30 pharmaceutical research companies' efforts to curb AMR across three research areas: research and development, manufacturing and production, and appropriate access and stewardship.
About Access to Medicine Foundation
The Access to Medicine Foundation is an independent non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle- income countries by stimulating and guiding the pharmaceutical industry to play a greater role in improving access to medicine.1
'Bye Bye Bugs' Educational App
The Pfizer medical team launched an anti-infective educational app, Bye Bye Bugs, in September 2018 via the UK Apple App store. It is a free educational game designed for junior Healthcare Professionals (HCPs) or senior HCPs who want to enhance their Antimicrobial Stewardship knowledge. The game simulates a virtual hospital-like scenario; through patient-based scenarios players diagnose infections and choose antimicrobial treatments. Feedback on decisions aims to improve learning and help understand the consequences of inappropriate antimicrobial treatment.
British Society for Antimicrobial Chemotherapy (BSAC) Antimicrobial Stewardship Massive Open Online Courses (MOOC)
We are proud to sponsor a collaboration with the British Society for Antimicrobial Chemotherapy and the University of Dundee on the development of an online educational course for healthcare professionals on antibiotic stewardship.2 Pfizer were the main consortium sponsor for the BSAC Antimicrobial Stewardship (AMS) MOOC when it launched in 2015, over 53,500 participants have enrolled for the AMS MOOC from over 200 countries. In addition, the AMS MOOC has been translated into a number of languages including Russian, Chinese and Portuguese. The AMS MOOC is just one of the BSAC educational programmes that Pfizer have sponsored.
Antimicrobial Susceptibility Testing (AST)
Launched in 2017, the Pfizer UK Antibiotic Susceptibility Testing (AST) programme provides NHS Trusts access to AST diagnostics in order to ensure responsible prescribing and support appropriate stewardship of our anti-infectives. The AST programme allows clinicians to inform their patient therapy decisions using commercially available AST diagnostic tests, and therefore to prescribe antibiotics appropriately. This will also help to protect the useful life of the antibiotic (from antibiotic resistance) by ensuring hospitals can exert appropriate stewardship.
If you would like to speak with one of the Pfizer team about how we can provide additional support, please contact us here to request a call back or email.
Antimicrobial Stewardship Toolkit
The AMS Toolkit contains a variety of resources aimed to offer tips and advice to HCPs looking to implement and maintain an AMS programme within the secondary healthcare setting. To access and download these resources, please click here
Understanding evolving resistance patterns is a key element in the quest to limit the rise of AMR.3
Antimicrobial Testing Leadership and Surveillance (ATLAS)
In 2017, Pfizer combined two global resistance surveillance programmes and launched the Antimicrobial Testing Leadership and Surveillance (ATLAS) website. It's one of the largest AMR surveillance programs in the world and has open access to healthcare workers, researchers and the global health community supporting easy access to critical resistance information. The system closely monitors global, regional and local resistance trends, allowing tracking of resistance and the main features include antimicrobial susceptibility geographic heat maps. ATLAS contains 15 years of continuous bacterial surveillance data, with more than 800 sites from over 75 countries. The data is updated every 6-8 months. ATLAS also contains 9 years of continuous fungal surveillance data, with more than 138 sites across over 40 countries.4
Pfizer and Wellcome launch surveillance programme to combat growing threat of Antimicrobial Resistance in Sub-Saharan Africa5
Pfizer and Wellcome have recently announced the launch of a multi-year, public-private research collaboration with the governments of Ghana, Kenya, Malawi and Uganda to track resistance patterns and better understand the burden of antimicrobial resistance (AMR) on patients living in low and middle-income countries.
This first-of-its kind partnership - known as Surveillance Partnership to Improve Data for Action on Antimicrobial Resistance (SPIDAAR) - will provide governments and health authorities with comprehensive data in four sub-Saharan African countries where there is a high burden of infectious diseases, insufficient data and lack of capacity to implement critically needed infection prevention and control programmes.
BSAC Resistance Surveillance Project
Specifically in the UK, Pfizer supported the BSAC Resistance Surveillance Project, which was a well-established program designed to provide long-term surveillance of antimicrobial resistance. Data are available for the last 20 years for an extensive list of bacterial pathogens.6
Access to Medicine Foundation: AMR Benchmark Report
Our surveillance efforts were recognised by the 2020 AMR Benchmark report. Pfizer were recognised as the ﬁrst company to share raw data on resistance collected via our open-access ATLAS surveillance program.1
- Access to Medicine Foundation. Antimicrobial resistance benchmark 2020. Available at: https://accesstomedicinefoundation.org/media/uploads/downloads/5f3f76733efaa_Antimicrobial_Resistance_Benchmark_2020.pdf [Last accessed July 2020].
- British Society for Antimicrobial Chemotherapy. Acknowledgements. Available at: http://www.bsac.org.uk/acknowledgements/ [Last Accessed July 2020]
- Review on Antimicrobial Resistance. Tackling drug-resistant infections globally: final report and recommendations. May 2016. Available at: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf [Last accessed July 2020]
- Pfizer. Antimicrobial Testing Leadership and Surveillance. Available at: https://atlas-surveillance.com/ [Last accessed July 2020]
- Pfizer and Wellcome Launch Surveillance Program to Combat Growing Threat of Antimicrobial Resistance in Sub-Saharan Africa. Available at: https://www.pfizer.co.uk/pfizer-and-wellcome-launch-surveillance-programme-combat-growing-threat-antimicrobial-resistance-sub [Last accessed July 2020]
- The British Society for Antimicrobial Chemotherapy. Resistance Survillance project. Available at: http://www.bsacsurv.org/ [Last accessed July 2020]
Zavicefta▼ (ceftazidime avibactam)
ZAVICEFTA® 2 g/0.5 g Powder for Concentrate for Solution for Infusion – SPC
Legal category: POM. Basic NHS price: 10 vial pack £857.00.
Cresemba 100mg hard capsules – SPC
Legal Category: POM. Basic NHS Cost:14 caps pack £599.28
Cresemba 200mg powder for concentrate for solution for infusion – SPC
Legal Category: POM Basic NHS Cost: 1 vial pack £297.84
Zinforo (ceftaroline fosamil)
Zinforo® 600 mg powder for concentrate for solution for infusion - SPC
Legal category: POM. Basic NHS cost: 10 vial pack £375.00
PP-AIP-GBR-0572. December 2020